• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Gilead Sciences

Gilead Sciences

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Gilead Announces Findings from New Preclinical Study Evaluating Novel Class of HIV Capsid Inhibitors

    Gilead Announces Findings from New Preclinical Study Evaluating Novel Class of HIV Capsid Inhibitors

  2. Gilead Presents New Phase 2 Data on Bictegravir, an Investigational Integrase Strand Transfer Inhibitor for the Treatment of HIV

    Gilead Presents New Phase 2 Data on Bictegravir, an Investigational Integrase Strand Transfer Inhibitor for the Treatment of HIV

  3. All eyes will be on Gilead's hepatitis C franchise as it reports fourth-quarter earnings

    All eyes will be on Gilead's hepatitis C franchise as it reports fourth-quarter earnings

  4. UPDATE: All eyes will be on Gilead's hepatitis C franchise as it reports fourth-quarter earnings

    UPDATE: All eyes will be on Gilead's hepatitis C franchise as it reports fourth-quarter earnings

  5. UPDATE: Nasdaq ekes out gains for new record, Dow hobbled by financials

    UPDATE: Nasdaq ekes out gains for new record, Dow hobbled by financials

  6. UPDATE: 5 reasons to bank on biotech stocks now

    UPDATE: 5 reasons to bank on biotech stocks now

  7. UPDATE: 5 reasons to bank on biotech stocks now

    UPDATE: 5 reasons to bank on biotech stocks now

  8. Janus Kinase (JAK) Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2017 - Research and Markets

    Janus Kinase (JAK) Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2017 - Research and Markets

  9. Gilead Posts Profit, Revenue Declines -- Update

    Gilead Posts Profit, Revenue Declines -- Update

  10. News Highlights: Top Company News of the Day

    News Highlights: Top Company News of the Day

12345

©2017 Morningstar Advisor. All right reserved.